A #MarchforScience participant talks about the need to stand up to anti-science policies, rhetoric
Without strong support for the sciences, our quest to transform basic research into meaningful new medicines will wither and die.
Steven Holtzman
Steven Holtzman joined Decibel as president and CEO in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through eight new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as the founder, CEO and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company.